Oncolytics Biotech stock rose 10% after the company secured a new US patent protecting pelareorep’s commercial manufacturing process into 2044.

Key Highlights

  • ONCY shares rose 9.75% to $0.93 during Tuesday trading after closing at $0.85.
  • The stock traded between $0.88 and $0.95, with volume reaching about 1.30 million shares.
  • The new US patent protects pelareorep’s proprietary manufacturing process into 2044.
  • A separate method-of-use patent application could extend protection into 2046 if issued.

Oncolytics Biotech Inc. (NASDAQ:ONCY) shares climbed during Tuesday trading after the clinical-stage biotechnology company announced a new US patent covering the commercial manufacturing process for pelareorep.

The stock traded at $0.93 in the latest regular-session update, up $0.08, or 9.75%, from the previous close of $0.85. Shares opened at $0.88 and moved between $0.88 and $0.95 during the session.

The patent was issued by the United States Patent and Trademark Office and covers key aspects of the company’s proprietary manufacturing methods for pelareorep. The protection is expected to extend into 2044.

Pelareorep is Oncolytics’ lead oncology asset. It is an investigational intravenously delivered double-stranded RNA immunotherapy designed to activate innate and adaptive immune responses against cancer.

The company said the manufacturing patent supports its ability to produce pelareorep at commercial scale. Manufacturing protection can be important for clinical-stage biotechnology companies preparing assets for later development and potential registration.

Oncolytics also said a previously filed method-of-use patent application remains under review. If issued, that application is expected to provide protection into 2046.

The company plans additional patent filings in 2026 to expand pelareorep’s intellectual-property estate across therapeutic applications, treatment settings and combination approaches.

Oncolytics is developing pelareorep in combination with chemotherapy and checkpoint inhibitors across gastrointestinal cancer indications. The therapy has received Fast Track designation for colorectal and pancreatic cancer indications.

The company has reported clinical data from studies in metastatic breast cancer, pancreatic cancer, colorectal cancer and anal cancer. Its current strategy remains focused on advancing pelareorep through partnership discussions and late-stage development planning.

The June 16 trading update valued Oncolytics at about $93.65 million. The stock has traded between $0.56 and $1.51 over the past 52 weeks.